30 Days of MD: Courtney Frazer
View this post on Instagram…
30 Days of MD: Courtney Frazer
Santhera Acquires Global Rights to DMD Therapy Vamorolone
Santhera Pharmaceuticals has obtained the worldwide rights to vamorolone (VBP15), an experimental therapy for Duchenne muscular dystrophy (DMD), the company announced. The company has reached an agreement with ReveraGen Biopharma, the original developer of vamorolone, and Actelion Pharmaceuticals’ spin-off Idorsia, which had acquired an…
September 6, 2020
by Kevin Schaefer
30 Days of MD: Ainaa Farhanah Amali
View this post on Instagram…
September is Duchenne Action Month
September is Duchenne Action Month, an awareness, fund-raising, and educational campaign supporting people with Duchenne muscular dystrophy (DMD) Hosted by Parent Project Muscular Dystrophy (PPMD), each week of the month is organized around a different theme, with scheduled events, as well as various resources and social media…
Recent Posts
- LGMD gene therapy gets FDA orphan drug designation
- An infected bug bite landed me in the ER, but I was in great hands
- Making adaptations while living with Duchenne muscular dystrophy
- Exon-skipping DMD therapy gets FDA orphan drug status
- An open letter to doctors who aren’t familiar with limb-girdle MD